[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of New Hampshire\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100648027","probiotic-response-in-periodontal-disease-100648027",false,"NCT07718074","Probiotic Response in Periodontal Disease","MicroPerio: Microbiome and Dietary Predictors of Probiotic Response in Periodontal Disease","MicroPerio","Inclusion Criteria:\n\n1. Age between 45 and 65 years: Restricting eligibility to this age range reduces potential confounding from age-related comorbidities and ensures adequate natural dentition for standardized gingival crevicular fluid (GCF) sampling.\n2. Diagnosis of Stage III periodontal disease (PD): Participants must have clinically confirmed Stage III (severe) PD according to the 2017 American Academy of Periodontology\u002FEuropean Federation of Periodontology (AAP\u002FEFP) classification system to ensure consistent disease severity among enrolled participants.\n\nExclusion Criteria:\n\n1. Use of prebiotic, probiotic, or fiber supplements within the previous 6 months: Recent use of microbiome-modulating supplements could alter baseline oral or gut microbial composition and confound assessment of responsiveness to the probiotic intervention.\n2. Use of antibiotics within the previous 6 months: Antibiotic exposure can cause sustained disruptions to host microbiomes and immune responses, which may confound evaluation of probiotic-related changes in inflammatory and microbial outcomes.\n3. Systemic diseases affecting the periodontium (uncontrolled diabetes mellitus defined as HbA1c ≥8%, autoimmune diseases): These conditions may independently influence periodontal inflammation, immune responses, and microbiome composition, potentially confounding interpretation of study outcomes.\n4. History of communicable or chronic diseases that may render study participation unsafe: Certain medical conditions may increase the risk of adverse events associated with study procedures or probiotic exposure.\n5. Pregnancy or breastfeeding: Physiological changes during pregnancy and lactation may influence periodontal status, immune function, and microbiome composition.\n6. Having fewer than 20 natural teeth: Adequate natural dentition is required to support standardized periodontal assessments and reliable biospecimen collection.\n7. Use of removable dentures: Denture use alters the oral microbiome and local inflammatory environment and may compromise the validity of periodontal outcome measures.\n8. Surgical periodontal disease treatment within the previous 6 months: Recent surgical intervention may induce substantial changes in the periodontal environment, complicating baseline measurement and interpretation of treatment response.\n9. Ongoing participation in another clinical trial: Concurrent participation in another trial may introduce overlapping interventions or behavioral changes that could compromise internal validity.\n10. Lack of mobility or physical independence: Physical limitations may make participation burdensome or interfere with attendance at study visits and completion of study procedures.\n11. Inability to communicate orally or in written English: Because study procedures and consent materials will be conducted in English, adequate language proficiency is required to ensure participants understand study instructions and provide informed consent.","ALL","45 Years","65 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","Probiotics are live microorganisms that can be taken as supplements and have shown promise in playing a beneficial role in improving clinical conditions that are characterized by chronic inflammation, such as periodontal disease (PD). The human gut microbiome is composed of trillions of bacteria that reside throughout the gastrointestinal tract and has an important role in the modulation of inflammatory responses in the human host. There is evidence that PD is associated with alterations in the oral and gut microbiomes, suggesting that probiotics may reduce inflammation through microbiome modulation. However, individual responses to probiotics can be highly variable, and robust predictors of probiotic responsiveness remain poorly defined. There is also limited knowledge about how the oral and gut microbiome interact even though there is growing evidence for a bidirectional oral-gut axis with implications for host immunity, inflammation, and probiotic responsiveness. The overarching goal of this project is to identify oral and gut microbiome features that predict responsiveness to probiotic interventions as an adjuvant treatment for PD. We will conduct a double-blind randomized controlled trial in which New Hampshire adults with stage III PD will be randomized to receive a 12-week adjuvant intervention of either a daily probiotic (n=45) or placebo (n=45) lozenge. The probiotic intervention will consist of a once daily lozenge containing a standard dose of 200 million CFU of two strains of Limosilactobacillus reuteri (DSM 17938 and ATCC PTA 5289), a commercial formulation demonstrated to be safe and well-tolerated in this population over this treatment length. The primary outcome to quantify responsiveness to the probiotic as an adjuvant therapeutic for PD will be within-subject change from baseline in inflammatory markers, and oral and gut microbiome composition.",[28],"Periodontal Disease",[30,31,32],"Periodontal disease","Probiotic","Microbiome","NOT_YET_RECRUITING","2026-07-16",{"date":36,"type":37},"2026-07-21","ACTUAL",{"date":39,"type":22},"2026-10",{"date":41,"type":22},"2028-07",{"name":43,"class":44},"University of New Hampshire","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100631686","evaluation-of-the-not-a-number-trafficking-prevention-program-in-minnesota-100631686","NCT07503912","Evaluation of the Not A Number Trafficking Prevention Program in Minnesota","Randomized Controlled Trial Evaluation of the Not A Number Trafficking Prevention Program in MN","Inclusion Criteria:\n\n* Age only\n\nExclusion Criteria:\n\n* None",true,"13 Years","17 Years",{"count":56,"type":22},450,[25],"Although the exact scope of commercial sexual exploitation of children (CSEC) remains unknown, its significant negative physical and emotional consequences for children has been well-documented. The U.S. government recognized the need for improved CSEC prevention over two decades ago and recent legislation has been introduced to further increase funding for prevention programs. However, there is little evaluation research to guide communities on best practices, and questions remain about how to most effectively approach primary prevention for CSEC.\n\nThis study involves a randomized controlled trial (RCT) evaluation of the Not a Number (NAN)- a CSEC prevention program. NAN, developed by the non-profit organization Love 146, is delivered nationally with a unique train-the-trainer model in Minnesota to reach youth at heightened risk for CSEC victimization.\n\nThe RCT will be conducted at 32 implementation sites (15 youth enrolled as participants per site, N=480), with sites randomly assigned to an implementation or a wait-list control condition. We will examine a range of program outcomes, including a reduction in CSEC victimization (primary outcome), through a pre-test\u002Fpost-test design (follow-up data collection at 6 weeks, 6 months, and 12 months).",[60],"Commercial Sexual Exploitation","2026-03-26",{"date":63,"type":37},"2026-03-31",{"date":65,"type":22},"2026-04-01",{"date":67,"type":22},"2027-09-30",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":52,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100509355","the-effects-of-an-obesogenic-lifestyle-in-recreationally-active-young-adults-100509355","NCT05912348","The Effects of an Obesogenic Lifestyle in Recreationally Active, Young Adults","Inclusion Criteria:\n\n* 18-30 years of age\n* Recreationally active completing 75-150 minutes of moderate-to-vigorous intensity exercise (\\>2 days\u002Fweek).\n* Fair cardiorespiratory fitness levels (Men: VO2\\>38.4 ml\u002Fkg\u002Fmin; Women: VO2\\>32.6 ml\u002Fkg\u002Fmin).\n\nExclusion Criteria:\n\n* Hypertension (resting or diagnosed)\n* Impaired fasting blood glucose (\\>100mg\u002FdL)\n* Diagnosed cardiovascular disease\n* Diagnosed diabetes\n* Diagnosed cancer\n* Diagnosed chronic kidney disease\n* Diagnosed musculoskeletal disorders that prevents the individual from exercising on a bike.","18 Years","30 Years",{"count":78,"type":22},45,[25],"This clinical trial aims to learn about the alterations in insulin resistance and metabolic flexibility following a transition to an obesogenic lifestyle in fit young men and women. The main questions it aims to answer are:\n\n1. Does adding excess carbohydrates when transitioning to a sedentary lifestyle promote insulin resistance and impaired 24hr glucose regulation in healthy men and women?\n2. Does adding excess carbohydrates when transitioning to a sedentary lifestyle lower the body's ability to break down fats and carbohydrates in healthy men and women?\n3. Does the added physical activity blunt shifts in carbohydrate and fat oxidation in healthy men and women?",[82,83,84,85],"Insulin Resistance","Impaired Glucose Tolerance","Obesity","Metabolic Disturbance","RECRUITING","2024-07-16",{"date":89,"type":37},"2024-07-17",{"date":91,"type":37},"2023-02-08",{"date":93,"type":22},"2026-09-30",{"name":43,"class":44},1,""]